Diagnostic imaging using a theranostic approach

Dr. Michael Samuel Hofman, Peter MacCallum Cancer Centre

In this interview, Dr. Hofman highlights the benefits of a theranostic approach. He further discusses the advantages of using Gallium as a radiotracer and explains why peptides are gaining increased attention as potential ligands in radiotracer and radioligand therapies. Concluding his talk, he shares his expert perspective on the optimal range for maximum standardized uptake value (SUV).

Targeting the CA IX surface protein

Dr. Darren R. Feldman - Memorial Sloan Kettering Cancer Center

In this interview, Dr. Feldman presents the merits of a theranostic approach for patients battling difficult-to-treat cancers. He further discusses the strengths of employing a CA IX-targeted strategy and shares his insights on the preliminary data from Part A of the GaLuCi Trial. Additionally, he explores how the CA IX radiotracer could significantly influence patient outcomes during the diagnostic phase.

Discover the latest GaLuCi Trial results

First-in-human safety, imaging and dosimetry of Debiopharm’s PET imaging agent (gallium-labelled, Debio 0328) a novel CA IX targeting peptide, in patients with clear cell renal cell carcinoma.

Leveraging the power of Radioligand Therapy 

Radioligand therapy (RLT) is a proven, exciting new modality that combines both precision medicine ‘You-treat-what-you-see’ approach and targeted therapy. The theranostic treatment approach has been shown to be effective and well-tolerated as it allows the treatment of only patients who express the right tumor biomarker.¹⁻⁴

Responding to high unmet needs

Current overall survival and patient outcomes are  insufficient in advanced  clear cell renal cell carcinoma (ccRCC),  Metastatic pancreatic ductal adenocarcinoma (PDAC) and metastatic colorectal cancer (CRC). Radioligand therapy has the potential to transform outcomes for these patients.10-30

Debiopharm’s theranostic pair is formed of a first-in-class radiopeptide (177Lu-labelled, D0228) combined with a PET imaging agent (68Ga-labelled, D0328) targeting the CA IX biomarker.5-9 The therapy is currently being investigated in the GaLuCi study, a first-in-human multicenter, non-randomized phase 1/2 clinical trial assessing safety and tolerability, imaging characteristics and the efficacy of the theranostic pair Debio 0228/0328 in patients with unresectable, locally advanced or metastatic solid tumors.


1. Garje et al. 2022 2. Hope et al. 2022 3. Novartis. 2018 4. Novartis. 2022 5. Muselaers et al. 2013 6. Muselaers et al. 2016 7. US Securities and Exchange commission 2023 8. Smith et al. 2023 9. Zhu et al. 2023 10. Lindenburg et al. 2019 11. Grunwald et al. 2018 12. Ruatta et al. 2019 13. Choueri et al. 2016 14. Kudo et al. 2018 15. Mortzer et al. 2013a 16. Mortzer et al. 2013b 17. Janjigian et al. 2018 18. Schachter et al. 2017 19. Ushio et al. 2021 20. Robatel and Schenk. 2022 21. Strapcova et al. 2020 22. Korkeila et al. 2009 23. Xie et al. 2020 24. Padala et al. 2020 25. Padala and Kallam, 2023 26. Ushio et al. 2021 27. Robatel and Schenk. 2022 28. Nguyen and Duong 2018 29. Noone et al. 2015 30. Kong et al. 2019 31. Van Kuiik et al. 2016 32. Korkeila et al. 2009 33. Lau et al. 2017 34. Bui et al. 2003  35. Strapcova et al. 2020 36. Globocan (2020) for epidemiology of the disease in US (all histological subtypes, no biomarker)